MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le Mée, S.
Right arrow Articles by Jacquemin-Sablon, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Mée, S.
Right arrow Articles by Jacquemin-Sablon, A.

Vol. 58, Issue 4, 709-718, October 2000

Cellular Resistance to the Antitumor DNA Topoisomerase II Inhibitor S16020-2: Importance of the N-[2(Dimethylamino)ethyl]carbamoyl Side Chain

Sandrine Le Mée, Françoise Chaminade, Charlotte Delaporte, Judith Markovits, Jean-Marie Saucier, and Alain Jacquemin-Sablon

Centre National de la Recherche Scientifique UMR 8532, Physico-chimie et Pharmacologie des Macromolécules Biologiques, Institut Gustave Roussy, Villejuif, France

The new olivacine derivative S16020-2 (NSC-659687) is a DNA topoisomerase II inhibitor endowed with a remarkable antitumor activity against various experimental tumors. In vitro physicochemical properties of this compound, in particular its interaction with DNA and DNA topoisomerase II, were very similar to those of ellipticine derivatives, except for a strictly ATP-dependent mechanism of cleavable complex induction. From the Chinese hamster lung fibroblast cell line DC-3F, a subline resistant to S16020-2, named DC-3F/S16, was selected by adding stepwise increasing concentrations of the drug to the cell growth medium. Whereas DC-3F/9-OH-E cells, a DC-3F subline resistant to 9-hydroxy-ellipticine, are cross-resistant to S16020-2, DC-3F/S16 cells are only very weakly cross-resistant to ellipticine derivatives, indicating that, despite their structural similarity, these compounds may differ in their mechanisms of action. Uptake and efflux rates of S16020-2 were identical in the resistant and the sensitive cells. Topoisomerase IIalpha was expressed at the same level in both sensitive and resistant cells, whereas expression of the beta -enzyme was approximately 50% lower in the resistant cells. Sequencing of both alpha - and beta -isoform cDNAs revealed a point mutation that converts Arg486 to a Gly in the alpha  cDNA, whereas the beta  cDNA was not modified. This amino acid substitution in a highly conserved sequence of the enzyme appears to be responsible for the resistance to S16020-2. Comparative analysis of the properties of the ellipticine and S16020-2-resistant cells suggests that S16020-2, which is a DNA intercalator, might also interact with this enzyme amino acid sequence through its side chain.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Chen, Y. Tang, M.-T. Wang, S. Zeng, and D. Nie
Human Pregnane X Receptor and Resistance to Chemotherapy in Prostate Cancer
Cancer Res., November 1, 2007; 67(21): 10361 - 10367.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. R. Kang and I. K. Chung
Down-Regulation of DNA Topoisomerase IIalpha in Human Colorectal Carcinoma Cells Resistant to a Protoberberine Alkaloid, Berberrubine
Mol. Pharmacol., April 1, 2002; 61(4): 879 - 884.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics